Aktimur, S. H. Et Al. 2016. The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.3 , 153-158.

Aktimur, S. H., Malkan, U. Y., Eyupoglu, D. N., HAZNEDAROĞLU, İ. C., KELKİTLİ, E., Atay, H. M., ... GÜNEŞ, G.(2016). The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.3, 153-158.

Aktimur, Sude Et Al. "The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases," UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.3, 153-158, 2016

Aktimur, Sude H. Et Al. "The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases." UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.3, pp.153-158, 2016

Aktimur, S. H. Et Al. (2016) . "The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases." UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.3, pp.153-158.

@article{article, author={Sude H. Aktimur Et Al. }, title={The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases}, journal={UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI}, year=2016, pages={153-158} }